

AUTHORIZATION UNDER SECTION 21.04 OF THE PATENT ACT

In the matter of application for authorization number CAMR-1 by Apotex, Inc. for export to Rwanda of the following pharmaceutical product:

- (a) if the pharmaceutical product is a drug as set out in section 2 of the *Food and Drugs Act*:
A fixed dose combination tablet of lamivudine (150 mg) + nevirapine (200 mg) + zidovudine (300 mg), as provided in Schedule 1 to the *Patent Act*
- (b) if the pharmaceutical product is a medical device:

1. I hereby authorize Apotex, Inc. whose postal address is


150 Signet Drive
Toronto, Ontario
M9L 1T9

to make, construct and use, the patented inventions identified in patent numbers 2,311,988; 2,070,230; 2,068,790; 2,286,126; 2,216,634; 2,105,487; 2,059,263; 2,009,637 and 2,030,056 solely for purposes directly related to the manufacture of the above-mentioned pharmaceutical product, and to sell it for export to the above-mentioned country or WTO Member.

2. The quantity of the pharmaceutical product authorized to be manufactured by this authorization is 15,600,000 tablets.

3. In accordance with section 21.09 of the Act, this authorization is valid for a period of two years, beginning on the date shown below.

Granted at Gatineau, Quebec, the 19th day of September, 2007



Mary Carman
Commissioner of Patents